Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Otsuka to acquire Avanir for $3.5 billion

Tuesday, December 2, 2014 11:32 AM

Tokyo-based Otsuka Pharmaceutical will acquire Avanir Pharmaceuticals of Aliso Viejo, Calif., for $17 per share in cash, for a total value of approximately $3.5 billion.

More... »


The CenterWatch Monthly, December 2014

Monday, December 1, 2014 01:45 PM

Growing adoption of feasibility review committees

More... »


Recipharm acquires Flamel Technologies facility in France

Monday, December 1, 2014 12:57 PM

Recipharm, a contract development and manufacturing organization based in Sweden, will purchase Flamel Technologies’ development and manufacturing facility in Pessac, France. Recipharm also will provide development and manufacturing support to Flamel under a long-term services agreement.

More... »

Grünenthal terminates license agreement with Actavis for cebranopadol

Monday, December 1, 2014 12:56 PM

Grünenthal, an independent, family-owned, international, research-based pharmaceutical company headquartered in Aachen, Germany, has terminated a license agreement with Actavis for the development and commercialization of cebranopadol, a novel analgesic for the treatment of chronic pain.

More... »

MESA Group acquires Spintech in Turkey

Monday, December 1, 2014 12:54 PM

Swiss-based MESA Group Holdings, a pan-European, independent, multi-vendor services provider, has acquired Spintech, a Turkish service provider for multi-vendor diagnostic imaging equipment, asset management and maintenance services.

More... »

Aeterna Zentaris, Sinopharm A-Think ink agreement

Monday, December 1, 2014 12:52 PM

Aeterna Zentaris, a specialty biopharmaceutical company based in Québec, and China-based Sinopharm A-Think Pharmaceuticals have signed of an exclusive license and technology transfer agreement for Aeterna Zentaris’ lead anti-cancer compound, zoptarelin doxorubicin, for the initial indication of endometrial cancer for the Chinese, Hong Kong and Macau markets (the territory). Zoptarelin doxorubicin, a novel synthetic peptide carrier linked to doxorubicin, currently is in a ZoptEC (zoptarelin doxorubicin in endometrial cancer) phase III trial in endometrial cancer.

More... »

Accovion launches new subsidiary in France

Monday, December 1, 2014 12:52 PM

Accovion, an independent, European, full-service CRO headquartered in Frankfurt, Germany, has established a new subsidiary in Lyon, France, as it continues its expansion across Europe. Together with offices in Italy, Poland, Russia, Romania, Spain, Czech Republic and the U.K., Accovion now is able to present itself with eight subsidiaries and overall coverage of 20 European countries.

More... »

Cancer Research U.K., AstraZeneca to collaborate

Monday, December 1, 2014 12:48 PM

AstraZeneca and Cancer Research U.K. have signed a memorandum of understanding through which Cancer Research U.K. drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AZ MRC U.K. Center for Lead Discovery to be built in Cambridge.

More... »

WuXi AppTec launches enhanced genomics services for Chinese researchers

Monday, December 1, 2014 12:39 PM

WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharma, biotech and medical device industries with operations in China and the U.S., has announced an enhancement to its genomics services. The WuXi Genome Center will provide Chinese researchers who use its gene sequencing services with access to the integrated sequence analysis capabilities of NextCODE Health, a bioinformatics company based in Cambridge, Mass.

More... »

The Importance of building relationships

Monday, December 1, 2014 07:00 AM

For decades, we have been tuned in to the importance of building relationships in everyday life and in business, but what does this really mean in the context of our important, day-to-day relationships in conducting clinical trials?

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs